Cognitive impairment and dementia in patients with Parkinson disease

James B. Leverenz, Joseph Quinn, Cyrus Zabetian, Jing Zhang, Kathleen S. Montine, Thomas J. Montine

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.

Original languageEnglish (US)
Pages (from-to)903-912
Number of pages10
JournalCurrent Topics in Medicinal Chemistry
Volume9
Issue number10
DOIs
StatePublished - 2009

Fingerprint

Parkinson Disease
Dementia
Movement Disorders
Neurodegenerative Diseases
Caregivers
Biomarkers
Quality of Life
Survival
Cognitive Dysfunction
Therapeutics

Keywords

  • Alzheimer disease
  • Cognitive impairment
  • Demenita with Lewy bodies
  • Dementia
  • Parkinson disease

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Cognitive impairment and dementia in patients with Parkinson disease. / Leverenz, James B.; Quinn, Joseph; Zabetian, Cyrus; Zhang, Jing; Montine, Kathleen S.; Montine, Thomas J.

In: Current Topics in Medicinal Chemistry, Vol. 9, No. 10, 2009, p. 903-912.

Research output: Contribution to journalArticle

Leverenz, James B. ; Quinn, Joseph ; Zabetian, Cyrus ; Zhang, Jing ; Montine, Kathleen S. ; Montine, Thomas J. / Cognitive impairment and dementia in patients with Parkinson disease. In: Current Topics in Medicinal Chemistry. 2009 ; Vol. 9, No. 10. pp. 903-912.
@article{1d5a91107f06400d92fc7d7d4e6ac26b,
title = "Cognitive impairment and dementia in patients with Parkinson disease",
abstract = "Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.",
keywords = "Alzheimer disease, Cognitive impairment, Demenita with Lewy bodies, Dementia, Parkinson disease",
author = "Leverenz, {James B.} and Joseph Quinn and Cyrus Zabetian and Jing Zhang and Montine, {Kathleen S.} and Montine, {Thomas J.}",
year = "2009",
doi = "10.2174/156802609789378218",
language = "English (US)",
volume = "9",
pages = "903--912",
journal = "Current Topics in Medicinal Chemistry",
issn = "1568-0266",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Cognitive impairment and dementia in patients with Parkinson disease

AU - Leverenz, James B.

AU - Quinn, Joseph

AU - Zabetian, Cyrus

AU - Zhang, Jing

AU - Montine, Kathleen S.

AU - Montine, Thomas J.

PY - 2009

Y1 - 2009

N2 - Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.

AB - Parkinson disease (PD) is an already prevalent neurodegenerative disease that is poised to at least double over the next 25 years. Although best known for its characteristic movement disorder, PD is now appreciated commonly to cause cognitive impairment, including dementia, and behavioral changes. Dementia in patients with PD is consequential and has been associated with reduced quality of life, shortened survival, and increased caregiver distress. Here we review clinical presentation and progression, pathological bases, identification of genetic risk factors, development of small molecule biomarkers, and emerging treatments for cognitive impairment in patients with PD.

KW - Alzheimer disease

KW - Cognitive impairment

KW - Demenita with Lewy bodies

KW - Dementia

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=74249120831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74249120831&partnerID=8YFLogxK

U2 - 10.2174/156802609789378218

DO - 10.2174/156802609789378218

M3 - Article

C2 - 19754405

AN - SCOPUS:74249120831

VL - 9

SP - 903

EP - 912

JO - Current Topics in Medicinal Chemistry

JF - Current Topics in Medicinal Chemistry

SN - 1568-0266

IS - 10

ER -